SCHEMBL7187168

SCHEMBL7187168

N#Cc1cnc(Nc2ccc3[nH]ccc3c2)c([N+](=O)[O-])c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 6/20 0.49
▸ JAK2 O60674 2/20 0.44
▸ JAK3 P52333 2/20 0.44
▸ FLT1 P17948 4/20 0.43
▸ IMPDH2 P12268 1/20 0.43
▸ IMPDH1 P20839 1/20 0.43
▸ FGFR2 P21802 1/20 0.41
▸ FLT3 P36888 1/20 0.41
▸ LRRK2 Q5S007 2/20 0.41
▸ PRKCQ Q04759 3/20 0.41
▸ PRKCD Q05655 3/20 0.41
▸ HSF1 Q00613 1/20 0.41
▸ LYN P07948 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.40
▸ KDR P35968 1/20 0.39
▸ SYK P43405 1/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ PIK3CG P48736 1/20 0.39
▸ PRKCH P24723 1/20 0.39
▸ PRKCE Q02156 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2543201 0.83 LRRK2 (0.43) JAK2JAK3LRRK2HSF1TDP1
SCHEMBL2543205 0.81 CDK1 (0.46) JAK2JAK3LRRK2TDP1
SCHEMBL7367851 0.81 LRRK2 (0.58) EGFRIMPDH2IMPDH1LRRK2PRKCQ
SCHEMBL7185783 0.81 EGFR (0.53) EGFRFLT1IMPDH2IMPDH1FGFR2
SCHEMBL8877814 0.78 MAPT (0.54) EGFRFLT1FGFR2FLT3HSF1
SCHEMBL29310772 0.76 POLB (0.46) JAK2JAK3LRRK2TDP1
SCHEMBL6996240 0.74 PRKCQ (0.57) EGFRLRRK2PRKCQPRKCDLYN
SCHEMBL7845762 0.73 GABRP (0.40) EGFRJAK2JAK3LRRK2TDP1
SCHEMBL2302600 0.72 CA1 (0.56) EGFRFLT1FGFR2FLT3KDR
SCHEMBL8542362 0.71 EGFR (0.48) EGFRFLT1FGFR2FLT3LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 — — US disclosed
EP-1196391-A1 BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-17 — — EP disclosed
WO-2001005770-A1 BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-25 — — WO disclosed
Send feedback